1. Home
  2. BXSL vs KNSA Comparison

BXSL vs KNSA Comparison

Compare BXSL & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone Secured Lending Fund of Beneficial Interest

BXSL

Blackstone Secured Lending Fund of Beneficial Interest

HOLD

Current Price

$23.43

Market Cap

5.5B

Sector

Finance

ML Signal

HOLD

Logo Kiniksa Pharmaceuticals Ltd.

KNSA

Kiniksa Pharmaceuticals Ltd.

HOLD

Current Price

$63.46

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BXSL
KNSA
Founded
2018
2015
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
4.9B
IPO Year
2018
2018

Fundamental Metrics

Financial Performance
Metric
BXSL
KNSA
Price
$23.43
$63.46
Analyst Decision
Buy
Strong Buy
Analyst Count
10
7
Target Price
$27.18
$60.86
AVG Volume (30 Days)
1.9M
1.0M
Earning Date
05-07-2026
04-28-2026
Dividend Yield
12.87%
N/A
EPS Growth
N/A
225.00
EPS
0.11
0.27
Revenue
N/A
$677,564,000.00
Revenue This Year
N/A
$37.48
Revenue Next Year
N/A
$17.87
P/E Ratio
$210.00
$242.04
Revenue Growth
N/A
60.09
52 Week Low
$22.47
$26.27
52 Week High
$32.81
$67.53

Technical Indicators

Market Signals
Indicator
BXSL
KNSA
Relative Strength Index (RSI) 48.69 59.95
Support Level $23.26 $42.67
Resistance Level $24.93 N/A
Average True Range (ATR) 0.46 3.06
MACD -0.05 0.40
Stochastic Oscillator 32.51 63.13

Price Performance

Historical Comparison
BXSL
KNSA

About BXSL Blackstone Secured Lending Fund of Beneficial Interest

Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies.

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Share on Social Networks: